Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. cadiss

CADISS SIGNED

A medical device for the selective dissection of pathological tissues and fibrosis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CADISS project word cloud

Explore the words cloud of the CADISS project. It provides you a very rough idea of what is the project "CADISS" about.

minimizing    weakens    hospital    hospitals    sub    rooms    optimize    people    space    optimal    shorter    30    reaching    dissection    critical    surrounding    true    10    thereby    involve    expansion    relying    auxin    damages    difficulties    incidence    23    cutting    150    pioneer    separated    grow    surgically    least    health    anesthesia    separation    cleavage    attributed    2016    saves    pathological    healthy    reducing    amounting    either    disease    2025    tissues    million    diseased    cagr    revenues    despite    assisted    cadiss    surgical    countries    revolutionary    force    risks    mechanical    9m    carefully    relapse    tissue    topical    patients    surgeon    repair    market    risk    tools    global    treatable    occupation    time    remove    drug    found    burden    complications    damage    mesna    period    money    5    plane    combines    replace    chemical    surgery    company    tearing    international    selective    chemically    dissecting    size    launch    undergo    adhesion    consisting    whereby    billion    valued    damaged    surgeries    save    organ   

Project "CADISS" data sheet

The following table provides information about the project.

Coordinator		 AUXIN SURGERY 

Organization address
address: RUE LOUIS DE GEER 6
city: LOUVAIN LA NEUVE
postcode: 1348
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Belgium [BE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AUXIN SURGERY BE (LOUVAIN LA NEUVE) coordinator 50˙000.00

Map

 Project objective

Surgery is the art of dissecting tissues in order to repair, remove, or replace a diseased or damaged organ. 30% of the global burden of disease can be attributed to surgically treatable conditions. More than 10% of surgical procedures involve critical dissection steps whereby the pathological tissue is carefully separated from the healthy surrounding tissues. These procedures together have an incidence of 150/100.000 people, amounting for 2 million surgeries per year in developed countries. Despite the importance of selective dissection in surgical procedures, the current tools are sub-optimal because they are all still relying either on tearing force or on non-selective cutting that can damage tissues. Auxin Surgery, a pioneer in novel dissection methods, has found a revolutionary system, CADISS, that combines mechanical force with the topical application of a chemical drug, Mesna that weakens adhesion between tissues thereby facilitating the dissection steps and minimizing the damages to health tissues. CADISS saves time, therefore patients need to undergo anesthesia for shorter period, thereby reducing the risks of complications. Moreover, hospitals save money on the usage of operating rooms and hospital personnel and can optimize the occupation of hospital space. The global general surgery devices market size was valued at over €10 billion in 2016 and is expected to grow at a CAGR of 8.5% by 2025. Chemically assisted dissection can be useful in most surgical procedures consisting in separation of two tissues along a cleavage plane and when at least one of these conditions is true: 1) the risk of relapse is present 2) the risk of side-effects through damage of healthy tissue is present or 3) the risk of facing difficulties for the surgeon is present. CADISS will bring our company to international expansion and growth reaching €23.9M in revenues 3 years after market launch.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CADISS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CADISS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

BeatsDigTherapeutics (2019)

Project SCALE: Tailored Digital Therapeutics for Neurological and Brain Disorders

Read More